Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Carfilzomib On Track For End-of-Year Submission After Surprising Top-line Phase II Results

This article was originally published in The Pink Sheet Daily

Executive Summary

Onyx's next-generation proteasome inhibitor shows a 24% response rate, 7.4 month durable response as a salvage therapy in multiple myeloma.

You may also be interested in...



Post-ASH, Onyx Has Grand Plans for Carfilzomib And Nexavar

Following a buoyant meeting at ASH, Onyx outlines its next steps as it strives to move from being a "one-product" company, to filing an NDA for a second cancer drug by mid-2011.

Post-ASH, Onyx Has Grand Plans for Carfilzomib And Nexavar

Following a buoyant meeting at ASH, Onyx outlines its next steps as it strives to move from being a "one-product" company, to filing an NDA for a second cancer drug by mid-2011.

Carfilzomib Works Well As Salvage Treatment; Momentum Builds For Frontline Role

Small study of Onyx' proteasome inhibitor shows potential for replacing Velcade in combination with Revlimid and dexamethasone in newly diagnosed multiple myeloma patients.

Related Content

Topics

UsernamePublicRestriction

Register

OM006764

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel